Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry. Article

Iyengar, SS, Nair, Tiny, Sathyamurthy, I et al. (2009). Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry. . 61(5), 480-481.

cited authors

  • Iyengar, SS; Nair, Tiny; Sathyamurthy, I; Hiremath, JS; Jadhav, U; Kumbla, D; Jain, RK; Srinivasan, M; Sahoo, PK; Chawla, Kamaldeep; Katiyal, VK

authors

abstract

  • Objective

    to study the efficacy and safety of indigenously developed tenecteplase injection in the management of Indian STEMI patients in clinical practice.

    Methods

    post-licensure, observational, prescription event monitoring study.

    Results

    2100 patients received weight-adjusted tenecteplase injection. More than 90% patients received aspirin, clopidogrel, and enoxaparin/heparin. Clinically successful thrombolysis was reported in 86.71%, in-hospital mortality was 3.48%. The adverse events recorded were comparable with previously published data. Any bleeding (excluding intra-cranial hemorrhage) was seen in 4.62% patients which was reported in 0.90% patients of which 47.34% patients had also received GpIIb/IIIa inhibitors.

    Conclusion

    This study confirms the efficacy and safety of indigenous tenecteplase in Indian STEMI patients.

publication date

  • September 1, 2009

keywords

  • Aged
  • Female
  • Fibrinolytic Agents
  • Humans
  • India
  • Male
  • Middle Aged
  • Myocardial Infarction
  • Registries
  • Tenecteplase
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator
  • Treatment Outcome

Medium

  • Print

start page

  • 480

end page

  • 481

volume

  • 61

issue

  • 5